# NewLink Genetics Corporation clinical trials: 34 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 34 trials with NewLink Genetics Corporation as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by NewLink Genetics Corporation: 34 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/newlink-genetics-corporation

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 34
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 34, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| February 25, 2019 | NCT03852446 | Single Ascending Dose PK, Oral Bioavailability and Food Effect Study in Healthy Male Volunteers | NewLink Genetics Corporation | Early phase 1 | Completed | Healthy | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03852446) |
| December 13, 2017 | NCT03372239 | Oral Bioavailability,and Food Effect Study and Single Ascending Dose PK Study in Healthy Male Volunteers | NewLink Genetics Corporation | Phase 1 | Completed | Healthy | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03372239) |
| October 4, 2017 | NCT03301636 | A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma | NewLink Genetics Corporation | Phase 2 | Terminated | Melanoma | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03301636) |
| May 24, 2017 | NCT03165188 | Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy | NewLink Genetics Corporation | Observational | Terminated | Pancreatic Cancer | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03165188) |
| May 23, 2017 | NCT03164603 | NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors | NewLink Genetics Corporation | Phase 1 | Completed | Solid Tumor | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03164603) |
| July 18, 2016 | NCT02835729 | A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia | NewLink Genetics Corporation | Phase 1 | Completed | Acute Myeloid Leukemia | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02835729) |
| January 7, 2016 | NCT02648711 | Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors | NewLink Genetics Corporation | Phase 1 | Terminated | Solid Tumors | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02648711) |
| July 20, 2015 | NCT02502708 | Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors | NewLink Genetics Corporation | Phase 1 | Completed | Glioblastoma Multiforme, Glioma, Gliosarcoma, Malignant Brain Tumor, Ependymoma, Medulloblastoma, Diffuse Intrinsic... | 81 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02502708) |
| June 2, 2015 | NCT02460367 | Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer | NewLink Genetics Corporation | Phase 1 | Terminated | Non-small Cell Lung Cancer, Progression of Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Recurrent | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02460367) |
| April 1, 2015 | NCT02405585 | Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer | NewLink Genetics Corporation | Phase 2 | Terminated | Pancreatic Cancer, Pancreatic Carcinoma Non-resectable | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02405585) |
| March 17, 2015 | NCT02389985 | A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian... | NewLink Genetics Corporation | Phase 1/2 | Terminated | Ovarian Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02389985) |
| March 5, 2015 | NCT02380677 | Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors | NewLink Genetics Corporation | Phase 1/2 | Terminated | Advanced Solid Tumor Malignancy | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02380677) |
| July 11, 2014 | NCT02187302 | CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC) | NewLink Genetics Corporation | Phase 2 | Completed | Metastatic Renal Cell Carcinoma | 115 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02187302) |
| March 4, 2014 | NCT02077881 | Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer | NewLink Genetics Corporation | Phase 1/2 | Completed | Metastatic Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer | 157 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02077881) |
| February 27, 2014 | NCT02073123 | Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma | NewLink Genetics Corporation | Phase 1/2 | Completed | Metastatic Melanoma, Stage III Melanoma, Stage IV Melanoma | 131 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02073123) |
| February 4, 2014 | NCT02054520 | Immunotherapy Study for Patients With Stage IV Melanoma | NewLink Genetics Corporation | Phase 2 | Terminated | Stage IV Melanoma, Metastatic Melanoma | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02054520) |
| February 3, 2014 | NCT02052648 | Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors | NewLink Genetics Corporation | Phase 1/2 | Completed | Glioblastoma Multiforme, Glioma, Gliosarcoma, Malignant Brain Tumor | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02052648) |
| January 14, 2014 | NCT02035358 | Immunotherapy Study for Metastatic Renal Cell Cancer | NewLink Genetics Corporation | Phase 1 | Completed | Metastatic Renal Cell Carcinoma, Metastatic Clear-cell Renal Cancer, Recurrent Renal Cell Carcinoma, Refractory Renal... | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02035358) |
| April 19, 2013 | NCT01836432 | Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer | NewLink Genetics Corporation | Phase 3 | Terminated | Pancreatic Cancer, Pancreatic Carcinoma Non-resectable, Locally Advanced Malignant Neoplasm | 302 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01836432) |
| February 15, 2013 | NCT01792050 | Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer | NewLink Genetics Corporation | Phase 2 | Completed | Metastatic Breast Cancer | 169 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01792050) |
| January 24, 2013 | NCT01774578 | Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer | NewLink Genetics Corporation | Phase 2/3 | Terminated | Non-small Cell Lung Cancer, Progression of Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Recurrent | 135 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01774578) |
| June 27, 2011 | NCT01380769 | A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer | NewLink Genetics Corporation | Phase 2 | Completed | Non-Small Cell Lung Cancer | 157 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01380769) |
| February 22, 2010 | NCT01072981 | Immunotherapy Study for Surgically Resected Pancreatic Cancer | NewLink Genetics Corporation | Phase 3 | Completed | Pancreatic Cancer | 722 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01072981) |
| September 16, 2008 | NCT00753740 | Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients. | NewLink Genetics Corporation | Phase 2 | Withdrawn | Cancer, Ovarian Cancer, Solid Tumor | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00753740) |
| August 22, 2008 | NCT00739609 | IDO Inhibitor Study for Relapsed or Refractory Solid Tumors | NewLink Genetics Corporation | Phase 1 | Terminated | Breast Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Solid Tumors | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00739609) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 8 |
| Phase 1/2 | 11 |
| Phase 2 | 10 |
| Phase 2/3 | 1 |
| Phase 3 | 2 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 19 |
| Terminated | 14 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Pancreatic Neoplasms | 10 |
| Carcinoma, Non-Small-Cell Lung | 6 |
| Melanoma | 6 |
| Neoplasms | 5 |
| Breast Neoplasms | 4 |
| Ovarian Neoplasms | 3 |
| Recurrence | 3 |
| Lung Neoplasms | 3 |
| Carcinoma, Renal Cell | 2 |
| Neoplasm Metastasis | 2 |
| Glioblastoma | 2 |
| Glioma | 2 |
| Gliosarcoma | 2 |
| Brain Neoplasms | 2 |
| Prostatic Neoplasms | 2 |
| Leukemia, Myeloid, Acute | 1 |
| Adenocarcinoma of Lung | 1 |
| Carcinoma, Squamous Cell | 1 |
| Carcinoma, Large Cell | 1 |
| Kidney Neoplasms | 1 |
| Colonic Neoplasms | 1 |
| Endometrial Neoplasms | 1 |
| Skin Neoplasms | 1 |
| Thyroid Neoplasms | 1 |
| Adenocarcinoma | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Language schools in the United States](https://specstream.ai/data/businesses/language-schools/united-states)
- [Physical therapy clinics in the United States](https://specstream.ai/data/businesses/physical-therapy-clinics/united-states)
- [Stucco contractors in the United States](https://specstream.ai/data/businesses/stucco-contractors/united-states)
- [Apparel manufacturers in the United States](https://specstream.ai/data/businesses/apparel-manufacturers/united-states)
- [Cement suppliers in the United States](https://specstream.ai/data/businesses/cement-suppliers/united-states)
- [Event technology companies in the United States](https://specstream.ai/data/businesses/event-technology-companies/united-states)
